Market Overview

Analyst Lays Out Pros, Cons Of The CVS-Aetna Deal

Analyst Lays Out Pros, Cons Of The CVS-Aetna Deal
Related AET
The Health Care Stocks With A Lot Riding On The Midterm Elections
8 Biggest Price Target Changes For Wednesday
Tracking George Soros's Portfolio - Q3 2018 Update (Seeking Alpha)
Related CVS
Barron's Picks And Pans: Apple, Amgen, TreeHouse Foods And More
Mid-Afternoon Market Update: On Deck Capital Jumps On Earnings Beat; Invacare Shares Plummet
Blow To The Renault-Nissan-Mitsubishi Alliance (Wall Street Breakfast Podcast) (Seeking Alpha)

CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET) agreed to merge over the weekend, and some of Wall Street's top analysts released their initial take on the deal.

The Analyst

Baird's Eric Coldwell maintains a Neutral rating on CVS' stock with an unchanged $77 price target.

The Thesis

CVS has plenty of challenges it needs to address moving forward, but the merger with Aetna creates some "interesting angles to differentiate and innovate," Coldwell said in a Monday note. But at the same time, the deal brings a lot of uncertainty at a hefty price tag, with minimal accretion until 2020, he said. 

Here are some positives Coldwell identified in the deal:

  • CVS' already has a deep relationship with Aetna, which would make a transition smooth.
  • Benefits from the combination of medical and pharmacy claims.
  • Improvements in big data and analytics.
  • A differentiated concept versus the competition.

A strong counter to, Inc. (NASDAQ: AMZN) if it decides to enter the space.

Coldwell said the negatives in a CVS-Aetna merger are:

Regulatory scrutiny.

  • A very large investment in MinuteClinic expansion and store design.
  • Concerns surrounding consumer choice, cost and ability to steer behavior.
  • The possibility the merger is a "desperation move" from CVS.
  • The potential for CVS to buying a managed care property near the top.

Price Action

Shares of CVS were trading lower by nearly 3 percent Monday morning, while shares of Aetna were higher by around 2.5 percent.

Related Links:

Analysis: A CVS-Aetna Merger Would Be Revolutionary

What To Make Of The Rumored CVS Bid For Aetna

Latest Ratings for AET

Oct 2018Credit SuisseMaintainsNeutralNeutral
Oct 2018CitigroupMaintainsNeutralNeutral
Oct 2018PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Baird Eric ColdwellAnalyst Color News Price Target Reiteration M&A Analyst Ratings Best of Benzinga


Related Articles (AMZN + AET)

View Comments and Join the Discussion!

Latest Ratings

BKNGWells FargoUpgrades0.0
DARJP MorganUpgrades25.0
HPCredit SuisseUpgrades65.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Maxim Group: No Fundamentals Behind Recent Spike In Pyxis Tankers

Amazon's Traffic, Mindshare Could Be A 'Huge' Opportunity For Aaron's